175,204 Shares in McKesson Corporation $MCK Bought by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab bought a new stake in McKesson Corporation (NYSE:MCK) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 175,204 shares of the company’s stock, valued at approximately $135,352,000. McKesson accounts for about 2.1% of Danica Pension Livsforsikringsaktieselskab’s holdings, making the stock its 17th biggest position. Danica Pension Livsforsikringsaktieselskab owned 0.14% of McKesson as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MCK. J.W. Cole Advisors Inc. grew its stake in McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after acquiring an additional 1,329 shares during the period. Private Wealth Partners LLC raised its position in shares of McKesson by 5.6% during the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after purchasing an additional 1,682 shares during the period. AlphaQuest LLC raised its position in shares of McKesson by 91.2% during the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of McKesson by 12.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after purchasing an additional 36,451 shares in the last quarter. Finally, CW Advisors LLC grew its position in shares of McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock valued at $8,067,000 after purchasing an additional 8,130 shares during the period. Institutional investors own 85.07% of the company’s stock.

McKesson Stock Down 0.1%

Shares of MCK stock opened at $942.57 on Wednesday. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The company’s fifty day simple moving average is $898.61 and its 200-day simple moving average is $830.00. The firm has a market cap of $115.45 billion, a PE ratio of 27.11, a P/E/G ratio of 1.52 and a beta of 0.38.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same period in the previous year, the business earned $8.03 EPS. The company’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio is 9.43%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on MCK shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Raymond James Financial set a $970.00 price target on shares of McKesson in a report on Thursday, March 5th. Weiss Ratings downgraded shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Wells Fargo & Company boosted their price objective on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research report on Thursday, February 5th. Finally, Evercore reaffirmed an “outperform” rating on shares of McKesson in a research note on Thursday, March 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, McKesson currently has a consensus rating of “Moderate Buy” and an average price target of $960.93.

Insider Transactions at McKesson

In other McKesson news, Director Maria Martinez sold 349 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the transaction, the director owned 301 shares of the company’s stock, valued at $282,900.87. The trade was a 53.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,868 shares of company stock valued at $3,743,820. 0.08% of the stock is owned by insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.